STOCK TITAN

Palisade Bio, Inc. - PALI STOCK NEWS

Welcome to our dedicated page for Palisade Bio news (Ticker: PALI), a resource for investors and traders seeking the latest updates and insights on Palisade Bio stock.

Palisade Bio, Inc. (Symbol: PALI) is a clinical-stage biopharmaceutical company dedicated to developing therapeutic solutions aimed at preserving the integrity of the intestinal barrier. The company's primary focus is on innovative treatments for inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD).

Palisade Bio’s strategic product portfolio includes PALI-2108, a promising drug candidate currently under development for treating IBD conditions. The company is also actively researching PALI-1908, a potential therapeutic that may expand its impact in gastrointestinal health.

Recently, Palisade Bio announced significant progress in its pipeline and secured strategic partnerships to further its research and development efforts. Notably, Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the latest offering, underscoring the financial community's confidence in the company's vision and potential.

Palisade Bio's commitment to advancing healthcare solutions is backed by a robust team and dedicated research initiatives. The company frequently updates its stakeholders with the latest developments and forward-looking statements. For more information or inquiries, Jenene Thomas from the JTC Team, LLC can be contacted at 833-475-8247 or via email at PALI@jtcir.com.

Rhea-AI Summary

Palisade Bio (Nasdaq: PALI) has announced that it has received approximately $1.25 million after 445,000 common stock purchase warrants were exercised by shareholders. This financial boost is aimed at extending the company's cash runway into early 2024, aligning with the anticipated topline results from the Phase 2 study of LB1148, which targets post-surgical adhesions. The company is focused on developing therapies that enhance intestinal barrier integrity, with LB1148 showing promise in reducing complications associated with gastrointestinal surgeries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.81%
Tags
none
-
Rhea-AI Summary

Palisade Bio, Inc. (Nasdaq: PALI) has announced it has regained compliance with Nasdaq Listing Rules as of December 1, 2022. The company is focused on developing therapeutics for gastrointestinal complications, leveraging over three decades of research on intestinal barrier biology. Its lead program, LB1148, aims to neutralize digestive enzymes and mitigate intestinal damage, showing promising results in clinical studies for reducing post-surgical complications. The company emphasizes the potential for its therapies to transform treatment standards for related diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
none
-
Rhea-AI Summary

Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company, announced that the FDA has granted Fast Track designation for its drug LB1148. This designation aims to expedite the return of bowel function after gastrointestinal surgery. LB1148 acts as a broad-spectrum serine protease inhibitor, neutralizing digestive enzymes to potentially reduce abdominal adhesions. CEO JD Finley highlighted this as a key regulatory milestone, emphasizing the unmet need for safer therapeutic options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
81.9%
Tags
none
Rhea-AI Summary

Palisade Bio has appointed Herbert B. Slade, MD, FAAAAI as its new Chief Medical Officer. With over 25 years in the pharmaceutical industry, Dr. Slade previously served as a clinical advisor for the company, contributing to the development of LB1148, a treatment for gastrointestinal complications. His extensive experience includes regulatory negotiations with the FDA and EMA, as well as significant leadership roles in clinical research. This transition aims to advance LB1148's potential as a standard of care for post-surgical gastrointestinal issues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
management
-
Rhea-AI Summary

Palisade Bio has released an animated video detailing the therapeutic potential of LB1148, aimed at reducing adhesions in gastrointestinal (GI) tissues and speeding recovery after surgeries. LB1148, a novel oral formulation of tranexamic acid, targets digestive proteases to mitigate GI complications. Currently in Phase 2 clinical trials, the product shows promise in improving post-surgical bowel function. The company emphasizes LB1148's role in addressing unmet medical needs due to chronic protease activity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
none
-
Rhea-AI Summary

Palisade Bio (Nasdaq: PALI) announced a 1-for-50 reverse stock split effective November 15, 2022, at 4:01 PM ET. This move, approved by stockholders on October 4, aims to enhance the company's share price to comply with Nasdaq listing requirements. The split consolidates 50 shares into one, affecting all stockholders uniformly. The par value remains $0.01 per share, and no fractional shares will be issued. Palisade Bio is focused on developing GI therapies, with its lead program, LB1148, currently in a Phase 2 study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.5%
Tags
none
Rhea-AI Summary

Palisade Bio, Inc. (Nasdaq: PALI) reported its financial results for Q3 2022 and outlined updates on its clinical programs for LB1148. The company has paused enrollment in the Phase 3 study for bowel function recovery to standardize study protocols. Meanwhile, it prioritizes the U.S. Phase 2 adhesions study, with 31 of 70 patients enrolled, expecting interim data in H1 2023. As of September 30, 2022, cash reserves were $14.0 million, and the company incurred a net loss of $4.0 million, a decline from a net income of $8.1 million in 2021, amidst rising R&D costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Palisade Bio announced an executive leadership transition on October 10, 2022, as Thomas Hallam, Ph.D., stepped down as CEO. The board appointed JD Finley, the current CFO, as the interim CEO. Finley has been CFO since 2017 and played a significant role in the company's merger with Seneca Biopharma. Finley expressed commitment to advancing the clinical program for LB1148, a treatment for GI complications. The company will refocus on internal reorganization, leading to the cancellation of its presentation at the ACS Clinical Congress 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
management
-
Rhea-AI Summary

Palisade Bio (Nasdaq: PALI) announced its abstract acceptance for the American College of Surgeons Clinical Congress 2022, set for October 16-20 in San Diego, CA. The presentation, titled LB1148 An Enteral Protease Inhibitor Significantly Accelerated the Return of Bowel Function after Bowel Resection, will include significant Phase 2 clinical data. The data show that LB1148 notably speeds up recovery of gastrointestinal function post-bowel resection, with implications for ongoing Phase 3 studies. This reinforces Palisade's emphasis on addressing gastrointestinal complications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
Rhea-AI Summary

Palisade Bio announced the grant of equity options to two new non-executive employees, totaling 93,000 shares, under its 2021 Inducement Plan. The options, set at the closing stock price on the grant date, vest quarterly over three years. The company focuses on developing therapies for gastrointestinal complications, with its lead drug candidate, LB1148, in ongoing Phase 3 and Phase 2 clinical trials. The potential of LB1148 to improve postoperative bowel function and reduce abdominal adhesions positions the company as a significant player in gastrointestinal therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Palisade Bio (PALI)?

The current stock price of Palisade Bio (PALI) is $1.75 as of December 23, 2024.

What is the market cap of Palisade Bio (PALI)?

The market cap of Palisade Bio (PALI) is approximately 5.3M.

What is Palisade Bio, Inc.'s core business?

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing therapeutics to protect the integrity of the intestinal barrier.

What diseases is Palisade Bio targeting with its therapeutics?

The company focuses on treating inflammatory bowel diseases (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD).

What are the key products in Palisade Bio's portfolio?

Key products include PALI-2108 for IBD treatment and PALI-1908, which is currently in the research phase.

Who is the exclusive placement agent for Palisade Bio's latest offering?

Ladenburg Thalmann & Co. Inc. is acting as the exclusive placement agent for the offering.

How can I contact Palisade Bio for more information?

You can contact Jenene Thomas from the JTC Team, LLC at 833-475-8247 or via email at PALI@jtcir.com.

What stage is Palisade Bio in its development?

Palisade Bio is currently in the clinical stage of developing its therapeutic products.

Does Palisade Bio have any ongoing research projects?

Yes, Palisade Bio is actively researching PALI-1908 in addition to developing PALI-2108 for IBD treatment.

What recent achievements has Palisade Bio announced?

The company has announced significant progress in its drug pipeline and secured strategic partnerships to further research and development.

What is the significance of PALI-2108?

PALI-2108 is a promising drug candidate specifically being developed to treat inflammatory bowel diseases like UC and CD.

Who are the target stakeholders for Palisade Bio's updates?

The target stakeholders include investors, medical professionals, and partners interested in the company's advancements and therapeutic developments.

Palisade Bio, Inc.

Nasdaq:PALI

PALI Rankings

PALI Stock Data

5.28M
1.31M
1.88%
3.58%
2.82%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CARLSBAD